In Patients 1 and 3, in which both tumor neoantigen-specific CD4+ and CD8+ T cells were activated and proliferated after the hybrid neoantigen-pulsed DC vaccine, a remarkable antitumor effect was sustained. The gene discussed is CD8A; the disease is neoplasm.